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BACKGROUND & AIMS: Studies reporting that budesonide is
effective for the treatment of collagenous colitis have been small
and differed in efﬁcacy measures. Mesalamine has been pro-
posed as a treatment option for collagenous colitis, although its
efﬁcacy has never been investigated in placebo-controlled trials.
We performed a phase 3, placebo-controlled, multicenter study
to evaluate budesonide and mesalamine as short-term treat-
ments for collagenous colitis. METHODS: Patients with active
collagenous colitis were randomly assigned to groups given pH-
modiﬁed release oral budesonide capsules (9 mg budesonide
once daily, Budenofalk, n ¼ 30), mesalamine granules (3 g
mesalamine once daily, Salofalk, n ¼ 25), or placebo for 8 weeks
(n ¼ 37) in a double-blind, double-dummy fashion. The study
was conducted in 31 centers (hospital clinics and private prac-
tices) in Germany, Denmark, Lithuania, Spain, and the United
Kingdom. The primary end point was clinical remission at 8
weeks deﬁned as 3 stools per day. Secondary end points
included clinical remission at 8 weeks, according to the
Hjortswang-Criteria of disease activity, taking stool consistency
into account. RESULTS: A greater percentage of patients in the
budesonide group were in clinical remission at week 8 than the
placebo group (intention-to-treat analysis, 80.0% vs 59.5%; P ¼
.072; per-protocol analysis, 84.8% vs 60.6%; P ¼ .046). Based on
the Hjortswang-Criteria, 80.0% of patients given budesonide
achieved clinical remission compared with 37.8% of patients
given placebo (P ¼ .0006); 44.0% of patients given mesalamine
achieved clinical remission, but budesonide was superior to
mesalamine (P ¼ .0035). Budesonide signiﬁcantly improved
stool consistency and mucosal histology, and alleviated abdom-
inal pain. The rate of adverse events did not differ among groups.
CONCLUSIONS: Oral budesonide (9 mg once daily) is effective
and safe for short-term treatment of collagenous colitis. Short-
term treatment with oral mesalamine (3 g once daily) appears
to be ineffective. ClinicalTrials.gov number, NCT00450086.
Keywords: Therapy; Clinical Trial; Drug; Microscopic Colitis.ollagenous colitis, a subgroup of microscopic colitis,Cis a chronic inﬂammatory bowel disease characterized
by chronic watery diarrhea and few or no endoscopic ab-
normalities. A considerable number of patients suffer from
additional symptoms, such as abdominal pain, nocturnal
diarrhea, fecal incontinence, and weight loss.1,2 Due to the
symptom burden, collagenous colitis impairs the patient’s
quality of life signiﬁcantly, in a manner similar to other in-
ﬂammatory bowel diseases.3,4 Epidemiological studies from
Europe and North America suggest that microscopic colitis
is being increasingly diagnosed, with its incidence and
prevalence rates similar to those of other inﬂammatory
bowel diseases.5–8 Because of the signiﬁcant symptom
overlap between microscopic colitis and irritable bowel
syndrome/functional diarrhea, the true prevalence of
microscopic colitis might be underestimated.9,10
The strongest evidence of success in treating collagenous
colitis is currently available for budesonide, a locally active
corticosteroid with extensive ﬁrst-pass metabolism in the
liver and low systemic exposure. Three randomized,
placebo-controlled trials have shown that oral budesonide
at a dosage of 9 mg/d is effective for short-term treatment
in collagenous colitis.11–13 However, those trials were rela-
tively small and their study designs differed, as did their
deﬁnitions of treatment response.
Although oral mesalamine at various doses is frequently
used to treat microscopic colitis, its efﬁcacy has never been
formally evaluated in randomized placebo-controlled trials. A
prospective uncontrolled study reportedhigh response rates of
long-term treatment with mesalamine alone or in combination
with cholestyramine.14 However, several large retrospective
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than half of patients with microscopic colitis.15–17
The aim of our study was to evaluate and compare the
efﬁcacy and tolerability of short-term treatment of pH-
modiﬁed release oral budesonide capsules (9 mg budeso-
nide once daily) and mesalamine granules (3 g mesalamine
once daily) in collagenous colitis in a randomized, placebo-
controlled fashion.
Methods
All authors had access to the study data and reviewed and
approved the ﬁnal manuscript.
Study Design and Setting
This was a double-blind, double-dummy, randomized
placebo-controlled, comparative phase-3 clinical trial con-
ducted in 31 centers (hospital clinics and private practices) in
Germany, Denmark, Lithuania, Spain, and the United
Kingdom. The study protocol was conducted in accordance
with the International Conference on Harmonisation Guide-
line for Good Clinical Practice and was approved by the Ethics
Committee of the University of Hamburg, Germany, as well as
by the national ethics committees in the participating coun-
tries. The study protocol was registered at www.clinicaltrials.
gov (NCT00450086) and at www.clinicaltrialsregister.eu
(EudraCT 2006-004159-39).
Study Population
Men or women between 18 and 80 years of age were
eligible for randomization if they met all of the following in-
clusion criteria: >4 watery/soft stools on at least 4 days in the
week before baseline; >3 stools per day on average within the
last 7 days before baseline (anti-diarrheals had to have been
discontinued 2 weeks before baseline); chronic diarrhea for at
least 3 months before baseline; complete colonoscopy within
the last 12 weeks (originally 4 weeks; amended because re-
striction of time frame hindered recruitment and, in some
cases, clinical symptoms were reduced after colonoscopy and
did not reappear in due time) before baseline; histologically
conﬁrmed collagenous colitis (thickness of collagen band
>10 mm, degeneration of surface epithelium). Women of child-
bearing potential had to use appropriate contraceptive
methods. All participants provided written informed consent.
Exclusion criteria for participation included other signiﬁcant
colonic diseases (ie, polyps >2 cm, tumors, Crohn’s disease, ul-
cerative colitis, ischemic colitis), partial colonic resection, infec-
tious diarrhea, celiac disease (blood tests and/or duodenal
histology required), diarrhea caused by other organic diseases of
the gastrointestinal tract, treatment with budesonide, Boswellia
serrata extract, salicylates, steroids, antibiotics, cholestyramine,
nonsteroidal anti-inﬂammatory, or other immunosuppressant
drugs within the last 4 weeks before baseline, malignant disease,
severe comorbidity, abnormal hepatic function or liver cirrhosis,
renal insufﬁciency, active peptic ulcer disease, known intoler-
ance or resistance to study drugs, pregnancy, or breast-feeding.
Treatment Allocation and Open Label
For allocation of the participants, a computer-generated list
of random numbers was used, which had been prepared bycontract research organization with no clinical involvement in
the trial. Eligible patients were randomly assigned to 1 of 3
treatment groups at a 1:1:1 ratio. The study medication was
packed in boxes, and consecutively numbered for each patient
according to the randomization schedule. The investigators at
the centers enrolled the patients and dispensed the study
medication as per randomization schedule. Patients received
either budesonide 9 mg once daily (3  3 mg pH-modiﬁed
release capsules, Budenofalk) 30 minutes before breakfast or
mesalamine 3 g once daily (2 sachets each containing 1.5 g
mesalamine presented as a granule formulation, Salofalk) in the
morning or placebo for 8 weeks in a double-blind, double-
dummy fashion. Interim visits were made at weeks 2, 4, and 6.
Patients nonresponsive after 4 weeks were allowed to discon-
tinue the double-blind treatment and begin open-label treat-
ment with budesonide (Budenofalk) 9 mg once daily for 4
weeks. Patients in clinical remission at the end of double-blind
treatment entered a 16-week treatment-free follow-up phase,
which included clinical visits after 8 and 16 weeks and in case
of symptom relapse, ie, >4 watery/soft stools on at least 4 days
in the week before the visit and >3 stools per day within the
last 7 days before the visit. Patients with symptom relapse
underwent open-label treatment with budesonide (Budenofalk)
9 mg once daily for 4 weeks. Adherence to the study treatment
was monitored by pill count at each study visit and patient
diaries. During the entire study period, the use of other anti-
inﬂammatory drugs, immunosuppressants, cholestyramine,
anti-diarrheals, other drugs causing constipation, and nonste-
roidal anti-inﬂammatory drugs (for more than 2 weeks; except
acetylsalicylic acid up to 100 mg/d and paracetamol for anal-
gesic use) was not permitted.
Endoscopy and Histology
A complete colonoscopy was performed at baseline (within
12 weeks before randomization) and, if possible, at the end of
the 8-week double-blind treatment. For patients who refused
the follow-up colonoscopy, we suggested sigmoidoscopy. At
each colonoscopy, biopsies were obtained from the terminal
ileum, cecum, the ascending, transverse, descending, and sig-
moid colon, and the rectum. In case of sigmoidoscopy, biopsies
were obtained from the sigmoid colon and rectum.
Biopsy specimens were ﬁxed in 10% formalin and
embedded in parafﬁn. Sections (5 mm) were stained with H&E.
Van Gieson staining was used to assess the collagen band. On
well-oriented sections in which at least 3 adjacent crypts were
cut in their vertical plane, we measured the thickness of the
collagen band (mm) and inﬂammation of the lamina propria
(semi-quantitative score 03). Histologic remission was
deﬁned as a collagen band thickness 10 mm and no inﬂam-
mation of the lamina propria with neutrophilic and eosinophilic
granulocytes. All biopsies were analyzed in blinded fashion by a
single pathologist (M.V.).
Clinical Outcomes Evaluation
Our primary end point was clinical remission (CR) at 8
weeks, deﬁned as a mean of 3 stools per day in the week
before the visit. Patients who stopped double-blind treatment
and switched to open-label treatment before the study end
point of 8 weeks were considered as nonresponders. Secondary
end points included CR at 8 weeks, according to the
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day, with <1 watery stool per day),18 prespeciﬁed in the sta-
tistical analysis plan. We added this new remission criterion
because the authors could show that the parameters stool
frequency and frequency of watery stools correlate best with
health-related quality of life in patients with collagenous colitis.
Additional end points were time to remission, number of
watery and solid stools per week, abdominal pain, histopa-
thology, tolerability and safety, symptom relapse during
treatment-free follow-up, and response to open-label budeso-
nide. An interim analysis was planned with 50% of total sample
size and conducted by an independent data monitoring
committee.
Safety Evaluation
At each clinic visit of the 8-week double-blind treatment as
well as open-label and follow-up phase, patients underwent
physical examination (at baseline and ﬁnal visit), vital signs,
previous (at baseline) and concomitant medications, and
adverse events were recorded, and general laboratory tests and
urinalysis were performed.
Statistical Analyses
This study was conducted using an adaptive 2-stage group
sequential test design with possible sample-size adaptation
after the interim analysis. Assuming rates of clinical remission
of 65% in the verum group (budesonide or mesalamine) and of
30% in the placebo group, the statistical power of the test
procedure was 80% with 16 patients per group in each of the
2 stages. Consequently, with a proposed sample size of 96
patients (3  32 patients) in the intention-to-treat (ITT) anal-
ysis, the study had 80% power to yield a statistically signiﬁcant
result. For hypothesis testing of the primary end point, the
overall (experiment-wise) type I error rate was 2-sided a ¼ .05.
All other statistical tests (Wald test for risk difference, Wil-
coxon signed rank test, log-rank test, Fisher’s exact test, t test)
were performed 2-sided with a signiﬁcance level of a ¼ .05 on
an exploratory basis.
Efﬁcacy was analyzed for the ITT population with a sensi-
tivity analysis for the per-protocol (PP) population. Patients
with lack of compliance, intake of forbidden concomitant
medication, violation of eligibility criteria, or early discontinu-
ation due to adverse event without causal relationship with
study drug, were excluded from PP population. Safety analysis
was performed descriptively for the safety population. Statis-
tical testing of the primary end point was done via the ADD-
PLAN system. All other analyses were conducted using the SAS
statistical package for Windows (SAS Institute, Cary, NC).Results
Patient Population
We randomized a total of 92 patients (budesonide 30,
mesalamine 25, placebo 37) eligible for ITT analysis. The
ﬁrst patient was enrolled on May 22, 2007. The last patient
left the study on June 21, 2011. Fifty-three patients were
considered for the interim analysis (budesonide 16, mesal-
amine 22, placebo 15). Recruitment continued during
analysis. The interim analysis revealed that mesalamine wasless effective than placebo and the conditional power to gain
a positive ﬁnal result was near zero (stopping by futility)
and, consequently, the independent data review board rec-
ommended closure of this study arm. A total of 15 patients
were considered as major protocol violators, leaving 77
patients for the PP analysis (Supplementary Figure 1). The
baseline demographic and clinical characteristics of the ITT
population were similar across the treatment groups
without any statistical differences among the 3 treatment
groups (Table 1, Supplementary Table 1). The patients’ drug
histories revealed the use of nonsteroidal anti-inﬂammatory
drugs or aspirin in 19 and 15 cases, respectively, with no
relevant differences among treatment groups. Only 3 pa-
tients were exposed to lansoprazole and none were exposed
to sertraline, ticlopidine, or acarbose. Thirty-one patients
were treated for the current acute episode before random-
ization. Eighteen of which (58.1%) received anti-diarrheals,
but only in 1 patient was efﬁcacy judged to be good or very
good.
Clinical Efﬁcacy
According to the primary end point, the proportion of
patients in CR at week 8 was higher with budesonide than
with placebo. The difference was statistically signiﬁcant in
the PP analysis, but did not quite reach signiﬁcance in the
ITT analysis (Figure 1A). The rate of CR with mesalamine
was lower than that with placebo at the interim analysis.
Budesonide was signiﬁcantly superior to mesalamine in the
ITT and PP analyses. According to the secondary end point
(CR by Hjortswang-Criteria), budesonide was signiﬁcantly
superior to both placebo and mesalamine in ITT and PP
analyses (Figure 1B).
The Kaplan-Meier analysis revealed that the time to CR
was signiﬁcantly shorter with budesonide (median 7 days)
compared with placebo (median 21 days; P ¼ .0144) or
mesalamine (median 24 days; P ¼ .0071) (Figure 2).
Budesonide signiﬁcantly reduced the mean number of
watery stools per week from 29.7 to 2.4 (P < .0001), and
increased the mean number of solid stools per week from
0.3 to 6.7 (P < .0001). Budesonide reduced the number of
days with watery stools per week substantially within the
ﬁrst 2 weeks of treatment (Figure 3). This effect was
mirrored by a signiﬁcant increase in the number of days
with solid stools per week within the ﬁrst 2 weeks of
budesonide treatment (Supplementary Figure 2).
On ITT analysis, the number of days with moderate-to-
severe abdominal pain within the week before assessment
was signiﬁcantly reduced from 1.8 to 0.8 (P ¼ .047) in pa-
tients receiving budesonide, and the placebo recipients
displayed no signiﬁcant change.
Histologic Features at Baseline and
Histologic Remission
The 3 treatment groups’ mean collagenous band thick-
ness and degree of chronic lamina propria inﬂammation
were similar at baseline. To examine the topographical
distribution of histologic features of collagenous colitis,
we analyzed a subgroup of patients who had had biopsies
Table 1.Baseline Demographic and Clinical Characteristics for Each Group
Characteristics
Budesonide
(n ¼ 30)
Mesalamine
(n ¼ 25)
Placebo
(n ¼ 37)
Total
(n ¼ 92)
Sex, n (%)
Male 5 (16.7) 7 (28.0) 4 (10.8) 16 (17.4)
Female 25 (83.3) 18 (72.0) 33 (89.2) 76 (82.6)
Age, y, mean (SD) 62.0 (13.1) 56.4 (13.3) 57.8 (12.3) 58.8 (12.9)
BMI, mean (SD) 25.2 (4.4) 25.1 (5.0) 24.2 (4.1) 24.8 (4.4)
Smoking habit, n (%)
Current 8 (26.7) 11 (44.0) 12 (32.4) 31 (33.7)
Former 7 (23.3) 4 (16.0) 10 (27.0) 21 (22.8)
Never 15 (50.0) 10 (40.0) 15 (40.5) 40 (43.5)
Caffeine intake, n (%) 28 (93.3) 24 (96.0) 32 (86.5) 84 (91.3)
Duration of symptoms, y, mean (SD) 2.7 (3.9) 4.7 (7.5) 3.7 (4.8) 3.6 (5.4)
New diagnosis, n (%) 21 (70.0) 19 (76.0) 25 (67.6) 65 (70.7)
Time since diagnosis, y, mean (SD) 0.6 (1.4) 1.4 (3.0) 1.9 (3.5) 1.3 (2.9)
Time since diagnosis, n (%)
<1 mo 20 (66.7) 14 (56.0) 20 (54.1) 54 (58.7)
1 to <12 mos 4 (13.3) 6 (24.0) 6 (16.2) 16 (17.4)
1 to <5 y 5 (16.7) 1 (4.0) 4 (10.8) 10 (10.9)
5 to <10 y 1 (3.3) 3 (12.0) 6 (16.2) 10 (10.9)
10 y 0 1 (4.0) 1 (2.7) 2 (2.2)
No. of previous episodes, mean (SD) 0.7 (2.0) 0.3 (0.7) 7.5 (30.3) 3.4 (19.8)
Previous episodes, n (%)
0 22 (73.3) 16 (64.0) 25 (67.6) 63 (68.5)
1 5 (16.7) 4 (16.0) 1 (2.7) 10 (10.9)
2 0 0 2 (5.4) 2 (2.2)
>2 2 (6.6) 1 (4.0) 8 (21.6) 11 (12.0)
Missing 1 (3.3) 4 (16.0) 1 (2.7) 6 (6.5)
BMI, body mass index.
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band thickness >10 mm in all 5 colonic segments was pre-
sent in 71.4% of patients, in 4 segments only in 11.9%,
in 3 segments only in 9.5%, and in only 1 or 2 segments
in 4.8% of patients. Virtually all patients had an at least
mild lymphoplasmacellular inﬂammation in 4 or 5 colonic
segments.
Follow-up biopsies were available from 63 patients
(budesonide 23, mesalamine 18, placebo 22), which allowed
paired analysis of pre- and post-treatment histology. Follow-
up biopsies were obtained from 46 patients from the right
and left colon, although left-side only biopsies were avail-
able from 17 patients (sigmoid, descending colon). Histo-
logic post-treatment remission was observed in 87% of the
budesonide patients, in 50% of the placebo recipients (P ¼
.0106), and in 45% of the mesalamine patients. In the
budesonide group, 78% of patients in clinical remission also
presented histologic remission. We observed no correlation
between clinical and histologic remission in patients taking
mesalamine or placebo (data not shown).
Safety
The rates of adverse events (AE) were similar among the 3
treatment groups (budesonide 47%, mesalamine 68%, pla-
cebo 54%; Table 2). None of the AE in the budesonide patients
were considered drug related, and 5 AEs with mesalamine
and 2 AEs with placebo were considered drug related. None of
the budesonide patients experienced a serious AE, and 3patients in the mesalamine group and 1 patient in the placebo
group experienced a serious AE. None of the serious AEs were
considered drug related. The most frequent AEs were head-
ache (budesonide 13%, mesalamine 16%, placebo 11%),
nasopharyngitis (budesonide 13%, mesalamine 12%, placebo
14%), and dyspepsia (budesonide 10%, mesalamine 12%,
placebo 3%). All other AEs were reported in 5 or fewer
patients (all treatment groups combined).
Follow-up and Open-Label Treatment
A total of 54 patients (Supplementary Figure 3) entered
the treatment-free follow-up phase. During follow-up, 19
patients (35%) experienced a symptom relapse, with a mean
of 24.4 watery/soft stools per week and a mean time to
relapse of 58 days. After 4 weeks of open-label budesonide
treatment, the mean frequency of watery stools decreased to
0.9 per week, with 14 patients achieving CR as deﬁned by
Hjortswang (ITT 74%). Another 26 patients (Supplementary
Figure 3) started open-label budesonide treatment after
premature discontinuation of the double-blind treatment
phase (n¼ 10) or immediately after the ﬁnal visit during the
double-blind phase (n ¼ 16), of which 8 (ITT 80%) and 11
(ITT 69%) patients achieved CR, respectively.Discussion
Our study conﬁrms the high efﬁcacy of budesonide for
the treatment of collagenous colitis in a multinational
Figure 1. (A) Clinical
remission (%) according to
the primary end point
deﬁnition (mean 3 stools
per day). (B) Clinical
remission (%) according to
the secondary end point
deﬁnition (mean <3 stools
per day, <1 of which was
watery stool).
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and, as demonstrated for the ﬁrst time for this indication, to
mesalamine as well for the primary end point in the PP
population and the vast majority of other secondary efﬁcacy
criteria in both ITT and PP populations. The primary end
point remission rate of budesonide observed in the ITT
population is similar to that reported from meta-analy-
ses.19–21 However, we failed to note a statistically signiﬁcant
difference due to an unexpectedly high placebo response
rate. One major reason for this high placebo response rate
might be due to our having deﬁned clinical remission by
stool frequency only. This end-point deﬁnition was chosen
arbitrarily when the study was initiated in 2007. Based on
intensive quality-of-life analyses, Hjortswang et al demon-
strated in 2009 that both stool frequency and stool consis-
tency are important when differentiating between disease
activity and remission in collagenous colitis.18 When theHjortswang-Criteria for remission were applied to our
study, we detected a highly signiﬁcant difference between
budesonide and placebo in both the ITT and PP populations.
Our ﬁndings support the notion that both stool frequency
and consistency are key when determining disease activity
and remission; they are probably more accurate than stool
frequency alone to differentiate between active intervention
and placebo in collagenous colitis.
There might be several reasons behind the high efﬁcacy
of budesonide in collagenous colitis. First, it exerts a well-
documented and potent anti-inﬂammatory effect in the
terminal ileum and right colon, as clearly shown in Crohn’s
disease.22 In microscopic colitis, there are data to suggest
that the histopathology might be more severe in the right
colon,23–25 and that some inﬂammatory changes can also
occur in the ileum.26,27 These observations might be rele-
vant to the local anti-inﬂammatory action of budesonide.
Figure 2. Time to clinical
remission.
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nide can also extend to the left colon, as suggested by
clinical studies in ulcerative colitis and collagenous coli-
tis.12,28 In addition, budesonide improves bile acid malab-
sorption, which might occur in a substantial number of
patients with microscopic colitis, by up-regulating the bile
acid transporter gene expression in the small bowel.29,30
Finally, there is evidence that budesonide improves the
small intestine’s water-absorption capacity, lowering the
ileostomy output in quiescent Crohn’s disease,31,32 as well
as alleviating chemotherapy-induced diarrhea refractory to
loperamide.33 Budesonide appears to exhibit an array of
pharmacological mechanisms likely to contribute to its
consistent clinical efﬁcacy in microscopic colitis.Figure 3. Number of days with watery stools in the week
before visit (ITT).Our study also conﬁrms the safety of short-term bude-
sonide treatment by revealing no signiﬁcant difference be-
tween the adverse-event rates of budesonide and placebo.
Budesonide’s favorable safety proﬁle has also been docu-
mented in placebo-controlled studies on short-term treat-
ment in collagenous and lymphocytic colitis,11–13,34,35 as
well as in studies addressing long-term treatment with
budesonide in collagenous colitis.36,37 A meta-analysis of
steroids in microscopic colitis conﬁrmed that in terms of
adverse events, budesonide was similar to placebo, and the
incidence of adverse events with prednisolone was about 5
times that with placebo.21 In addition, a recent population-
based US cohort study of 315 patients with microscopic
colitis demonstrated a higher response rate to budesonide
compared with prednisone and a lower relapse rate after
budesonide therapy compared with prednisone therapy.38
Based on this body of data, the European Microscopic
Colitis Group recently recommended budesonide as the
treatment of choice for active microscopic colitis.39 The re-
sults of this study support the therapeutic value for this
indication.
Our study is the ﬁrst to compare mesalamine with pla-
cebo in collagenous colitis. The clinical remission rate we
observed with mesalamine resembles the experience from
large retrospective series.15–17 However, there were no
statistically signiﬁcant differences from placebo in any of
the efﬁcacy criteria applied in our study, suggesting that
mesalamine is ineffective in collagenous colitis. In contrast,
a prospective single-center study reported a clinical
response in 8 of 9 patients with collagenous colitis taking
Table 2.Patients with Adverse Events by System Organ Class and Preferred Term Occurring in at Least 2 Patients in the
Double-Blind Phase
Adverse events
Budesonide
(n ¼ 30), n (%)
Mesalamine
(n ¼ 25), n (%)
Placebo
(n ¼ 37), n (%)
Total 14 (47) 17 (68) 20 (54)
Infections and infestations 6 (20) 6 (24) 9 (24)
Bronchitis 1 (3) 1 (4) —
Nasopharyngitis 4 (13) 3 (12) 5 (14)
Gastrointestinal disorders 5 (17) 7 (28) 7 (19)
Abdominal pain — — 2 (5)
Abdominal pain upper — 1 (4) 1 (3)
Constipation — 1 (4) 1 (3)
Diarrhea — — 2 (5)
Dyspepsia 3 (10) 3 (12) 1 (3)
Flatulence — 1 (4) 1 (3)
Vomiting — 2 (8) 2 (5)
Nervous system disorders 5 (17) 5 (20) 5 (14)
Dizziness 1 (3) 2 (8) —
Headache 4 (13) 4 (16) 4 (11)
Investigations 1 (3) 6 (24) 2 (5)
C-reactive protein increased — 3 (12) 2 (5)
Musculoskeletal and connective tissue disorders 4 (13) 1 (4) 4 (11)
Muscle spasms 2 (7) — —
Neck pain 1 (3) — 1 (3)
General disorders and administration site conditions 2 (7) 2 (8) —
Pyrexia — 2 (8) —
Respiratory, thoracic and mediastinal disorders 2 (7) 2 (8) —
Cough — 2 (8) —
Oropharyngeal pain 2 (7) — —
Psychiatric disorders 1 (3) 1 (4) 1 (3)
Ear and labyrinth disorders 1 (3) 1 (4) —
Vertigo 1 (3) 1 (4) —
Metabolism and nutrition disorders — 2 (8) —
Dehydration — 2 (8) —
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ﬁnding remains difﬁcult to appraise due to the lack of a
placebo-control group. To shed more light on the value of
mesalamine in microscopic colitis, our group is now
conducting a randomized placebo-controlled, multicenter
study to investigate mesalamine in lymphocytic colitis
(ClinicalTrials.gov number, NCT01209208).
The pharmacokinetic proﬁle of the test medication
budesonide (Budenofalk)40,41 differs from those of other
commercially available budesonide preparations (eg, Ento-
cort, Uceris).42,43 Budenofalk pellets release the active
ingredient budesonide only at a pH of 6.4 or higher,44 which
is reached in the terminal ileum. In contrast, Entocort starts
to release budesonide earlier than Budenofalk, and Uceris
targets primarily the colon.43 The release proﬁle of the
mesalamine formulation used in this study (Salofalk gran-
ules) is comparable with that of Apriso,45,46 but reveals
marked differences from other commercially available
mesalamine formulations (eg, Asacol, Pentasa).47,48 Given
the colonic topography of the disease and the topical action
of the test medication, it remains speculative whether the
efﬁcacy data achieved in our study can be extrapolated to
other budesonide or mesalamine formulations.In summary, our study conﬁrms that budesonide is
effective and safe for short-term treatment of collagenous
colitis. However, our study has failed to provide evidence of
the efﬁcacy of mesalamine in short-term therapy of collag-
enous colitis. Additional studies might be necessary to
elucidate the role of mesalamine in microscopic colitis.Supplementary Material
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Supplementary Figure 1. Study ﬂow of randomized patients.
Supplementary Figure 2. Number of days with solid stools in the week before visit (ITT).
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Supplementary Figure 3. Study ﬂow in follow-up and open-label phase.
Supplementary Table 1.Baseline Demographic and Clinical
Characteristics, P Values
Budesonide
vs placebo,
P value
Mesalamine
vs placebo,
P value
Overall
P value
Sex .4999a .1007a .2057a
Age .1521d .6511d .1980b
BMI .2971d .6893d .6217b
Smoking habit .7770c .5702c .6679c
Caffeine intake .4468a .3870a .4674a
Duration of symptoms .7240d .8746d .8725b
New diagnosis 1.0000a .5740a .8056a
Time since diagnosis .4194d .6877d .5479b
No. of previous episodes .3441d .3313d .5017b
BMI, body mass index.
aFisher’s exact test.
bKruskal-Wallis test.
cFisher’s exact test for smoking (current, former, never).
dWilcoxon Mann-Whitney test.
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